Caris Life Sciences announces Vall d´Hebron Institute of Oncology joins its precision oncology alliance


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Caris Life Sciences announces Vall d´Hebron Institute of Oncology joins its precision oncology alliance
The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research

Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Spain's Vall d´Hebron Institute of Oncology (VHIO) has joined Caris' Precision Oncology Alliance (The Alliance/POA). The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer.

Established in 2006, VHIO is a leading comprehensive research cancer center of excellence, where scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. Undertaking one of Spain´s most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of their patients.

"We are excited to welcome the Vall d' Hebron Institute of Oncology into the Alliance as we begin to expand the Caris POA network outside the U.S.," said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. "International members like VHIO, focused on advancing personalized and targeted therapies against cancer through innovation and research, support the Alliance's goal to expand broad-based collaboration among our member institutions in precision oncology research to improve outcomes for cancer patients worldwide."

"Our mission to provide improvements in the field of oncological diseases, and translate discoveries into medical benefits is enriched through partnerships like the Caris Precision Oncology Alliance. I strongly believe in joining forces, nurturing and developing partnerships, and exchanging data to overcome the many challenges that hamper our efforts in solving cancer sooner," said Josep Tabernero, M.D., Ph.D., VHIO's Director. "Understanding the unique molecular characteristics of tumors offers insights that can be used to better prevent and treat cancer for patients everywhere."

The Caris Precision Oncology Alliance includes over 40 cancer centers and academic institutions. These institutions have early access to Caris MAI (Molecular Artificial Intelligence) offerings, and establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence platform, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by Biopharma.

"Partnering with international institutes like Vall d'Hebron Institute of Oncology expands the capabilities for all Alliance members to access pioneering research that can both advance and accelerate personalized and targeted therapies to better treat cancer," said Brian J. Brille, Vice Chairman of Caris Life Sciences.

Tags : #CarisLifeSciences #LatestNewsonCarisLifeSciences1stDec #ValldHebronInstituteofOncology #LatestPharmaNews1stDec #LatestPharmaCollaboration1stDec #LatestNewsonCancerResearch1stDec #MolecularScience #Spain

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026